Fate of Biogen’s Stock Rides on Alzheimer’s Drug Decision
(Bloomberg) -- For Biogen Inc., the Food and Drug Administration's expected decision Monday on its Alzheimer's drug is what a JPMorgan Chase & Co. analyst called “the mother of all binary events” -- one that could send its shares veering sharply in either direction.
If regulators give the company approval to market the drug, called aducanumab, the stock could surge to as much to $450, according to Wall Street analysts. Or it could tumble to $200 if the treatment is shot down, according to Cory Kasimov, the JPMorgan analyst who follows the company.
The stock rose as much as 7% to $291.71 in Friday trading, it's the biggest intraday jump for Biogen since Jan. 29.
The forecasts reflect how heavily Biogen's outlook is tied to the drug, the first that's thought to slow the progression of the disease in people who show early signs of cognitive impairment. That's left Wall Street analysts and investors trying to weigh whether regulators will hasten its approval despite mixed reviews that whipsawed the company's stock late last year.
“The data package is insufficient, and with almost any other indication, we suspect regulators would be asking for another confirmatory trial pre-approval,” Kasimov wrote in a note.
“But this isn't any other indication. It's Alzheimer's. And the unmet need is rather unprecedented,” he wrote. “It's anyone's guess as to what happens next.”
Read more: Biogen's New Alzheimer's Drug Faces Hurdles Reaching Patients, Even if It's Approved
Biogen's stock has traded sideways since November, when it surged on an FDA staff report that said aducanumab appears effective, only to then tumble when an outside panel of agency advisers said the data from a single trial wasn't sufficient. But activity in bullish Biogen calls has picked up recently, suggesting the market is positioning ahead of the June 7 decision date.
The decision may also affect other drugmakers. Eli Lilly & Co. is working on its own early Alzheimer's drug, donanemab, which could be seen as having an easier path if Biogen's is approved. More volatile small-cap drugmakers are also pursuing their own treatments, including Cassava Sciences Inc., Annovis Bio Inc., Anavex Life Sciences Corp. and Prothena Corp.
The FDA decision is one of three near-term events that could help turn around sagging investor sentiment on the biotech industry, according to stock analysts. The other are depression trial results from Biogen and partner Sage Therapeutics Inc. and data expected from from Vertex Pharmaceuticals Inc. on a therapy forgenetic disorder.
The SPDR S&P Biotech ETF, which closely tracks smaller biotechs, has dropped 26% from February's record as investors shifted out of growth stocks that were highly favored during the depths of the pandemic.
“Buckle up for what's likely to be a very important month for biotech investing,” Kasimov said in a research note.
Read more: Biogen's New Alzheimer's Drug Faces Hurdles Reaching Patients, Even if It's Approved
Jefferies analyst Michael Yee also saw room for a sector turnaround ahead of the three catalysts. “If net positive, we could see sentiment get better as these are generally very liquid well-trafficked names and could cause the group to rally.”
If the three events are negative? He said the sector could fall by another 10%.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.